US Patent 11213502 Method for treatment of parkinson's disease
Patent 11213502 was granted and assigned to NeuroDerm on January, 2022 by the United States Patent and Trademark Office.
All edits
Edits on 13 Dec, 2023
Golden AI
Edits made to:
Article (+418 characters)
Article
Patent abstract
Disclosed is a method for the treatment of a neurological or movement disorder, e.g., Parkinson's disease, in an individual in need thereof, by parenteral administration of levodopa and a dopa decarboxylase inhibitor (DDCI), such as carbidopa, benserazide or any combination thereof, concomitantly with oral administration of levodopa, a DDCI, such as carbidopa, benserazide, or any combination thereof.
Edits on 15 Oct, 2023
Golden AI
Edits made to:
Infobox (+3 properties)
Infobox
Patent Inventor Names
Itay Perlstein0
Liat Adar0
Tal Birnberg0
Edits on 18 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 28 Apr, 2023
Golden AI
Infobox
Patent Citations Received
Edits on 31 Mar, 2023
Golden AI
Infobox
Patent Citations Received
Edits on 8 Oct, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 26 Sep, 2022
Golden AI
Infobox
Patent Citations Received
Edits on 17 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 18 May, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent citations received
Edits on 5 Jan, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 11213502 Method for treatment of parkinson's disease
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
11213502
Date of patent
January 4, 2022
Patent application number
17334554
Date Filed
May 28, 2021
Patent primary examiner
Find more entities like US Patent 11213502 Method for treatment of parkinson's disease
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.